Robert A Kurt
Overview
Explore the profile of Robert A Kurt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
366
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
De Sousa C, Blum C, Sgroe E, Crespo A, Kurt R
Cell Immunol
. 2010 Sep;
266(1):67-75.
PMID: 20869044
Although TLR are often studied on DC because of their ability to bridge innate and adaptive defenses, TLR are also expressed by epithelial cells. Because the majority of cancers are...
12.
Nair P, ODonnell C, Janasek K, Sajduk M, Smith E, GOLDEN J, et al.
Immunol Invest
. 2009 Oct;
38(8):730-48.
PMID: 19860585
Toll-like receptors (TLR) are pattern recognition receptors that play a pivotal role in the initiation of immune responses. Here we report that the murine mammary carcinoma 4T1 constitutively expressed genes...
13.
Goldstein B, Kurt R
Immunol Invest
. 2009 Oct;
38(5):365-82.
PMID: 19811414
Initially, we wanted to know whether dietary vitamin D(3) restriction would influence growth and metastasis of the 4T1 murine mammary carcinoma. We confirmed serum 25(OH)D levels were modulated by dietary...
14.
Golden J, LaCasse C, Simova D, Murphy T, Kurt R
Immunol Lett
. 2008 Apr;
118(1):30-5.
PMID: 18403024
Dendritic cells are key components of successful immunological responses bridging innate and adaptive defenses. In this study we wanted to know whether ligation of toll-like receptors (TLR) expressed by dendritic...
15.
Jayasinghe M, Golden J, Nair P, ODonnell C, Werner M, Kurt R
Breast Cancer Res Treat
. 2007 Nov;
111(3):511-21.
PMID: 17978871
Besides functioning as a chemotactic factor, CCL5 has been associated with progression of disease in women with breast cancer, immune modulation and metastasis. Here we asked whether CCL5 produced by...
16.
Cridge T, Horowitz K, Marinucci M, Rose K, Wells M, Werner M, et al.
Immunol Invest
. 2006 Mar;
35(1):115-32.
PMID: 16531333
To delineate whether, and the extent to which, CCL5 could impact T cell function we examined cytokine production and proliferative ability following CCL5 treatment in vitro. We report a decreased...
17.
Stormes K, Lemken C, Lepre J, Marinucci M, Kurt R
Breast Cancer Res Treat
. 2005 Feb;
89(2):209-12.
PMID: 15692764
To determine whether tumor-derived CCL5 contributes to the metastatic potential of murine mammary carcinoma, we used the 4T1 tumor which spontaneously metastasizes and constitutively produces CCL5. Mice bearing 4T1 that...
18.
Vitiello P, Rausch M, Horowitz K, Kurt R
Immunol Invest
. 2004 Jun;
33(2):235-49.
PMID: 15195699
In this study we were interested in investigating the extent to which stimulation through a chemokine receptor could modulate TCR function. We report that splenic T cells exposed to secondary...
19.
Vitiello P, Shainheit M, Allison E, Adler E, Kurt R
Immunol Lett
. 2004 Mar;
91(2-3):239-45.
PMID: 15019295
To study the effects of tumor-derived monocyte chemoattractant protein-1 (MCP-1, CCL2) on the anti-tumor immune response we used the 4T1 murine mammary carcinoma which constitutively expresses CCL2. We generated 4T1...
20.
Adler E, Lemken C, Katchen N, Kurt R
Immunol Lett
. 2003 Dec;
90(2-3):187-94.
PMID: 14687724
To investigate the role of tumor-derived CCL5 (regulated upon activation, normal T cell expressed and secreted, RANTES) in tumor immunity we compared the T cell response to tumors derived from...